Velnarin
The CANVAS Program, comprising two sister trials, was designed to assess the cardiovascular safety and efficacy of canagliflozin and to evaluate the balance between any potential benefits of the drug and the risks associated with it, such as genitourinary infection, diabetic ketoacidosis, and fracture.
Возможно, речь идет о двух исследованиях с одинаковым дизайном и/или с одинаковыми конечными точками.